We observed lower incidences of KDD in ERBB2, ERBB3 and ERBB4 than EGFR, with distributions mirroring those of other observed oncogenic mutations in brain tumors and NSCLC13–17 (Table 1a). The gene discussed is ERBB2; the disease is brain neoplasm.